An observational, prospective, open label, multicenter study to evaluate the safety and effectiveness of pegfilgrastim as secondary prophylaxis to decrease the incidence of febrile neutropenia in Korean female patients with breast cancer

CONCLUSION: The use of pegfilgrastim as secondary prophylaxis was effective and safe for preventing FN in patients with breast cancer who were treated with chemotherapy.PMID:37802015 | DOI:10.1016/j.breast.2023.103585

Source: Breast - October 6, 2023 Category: Cancer & Oncology Authors: Anbok Lee Taewoo Kang Su Hwan Kang Woo-Chan Park Woosung Lim Myung-Chul Chang Hyun Yul Kim Jeong-Yoon Song Jihyoun Lee Kyung Do Byun Hyun-Ah Kim Gil Soo Son Ju-Yeon Kim Se Jeong Oh Min Sung Chung Young Jin Choi Hyuk-Jai Shin Jong Min Baek Youngbum Yoo Eun Source Type: research